Peter Verdult analyst CITI

Currently out of the existing stock ratings of Peter Verdult, 18 are a BUY (64.29%), 7 are a HOLD (25%), 3 are a SELL (10.71%).

Peter Verdult

Work Performance Price Targets & Ratings Chart

Analyst Peter Verdult, currently employed at CITI, has had 37.5% of price targets met with an average potential upside of 10.87%, reached in 123 days on average. Previously, Peter Verdult worked at BARCLAYS.

Peter Verdult has documented 48 price targets and ratings displayed on 7 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on SNY, Sanofi ADR at 23-Apr-2026.

Wall Street Analyst Peter Verdult

Analyst best performing recommendations are on NVO (NOVO NORDISK A/S).
The best stock recommendation documented was for NVO (NOVO NORDISK A/S) on 8/13/2025. The price target of $54 was fulfilled within 9 days with a profit of $6.06 (12.64%), with a performance score of 14.05.

Average potential price target upside

GLPG Galapagos NV ADR GRFS Grifols SA ADR NVO Novo Nordisk A/S EVO Evotec SE ADR GMAB Genmab AS SNY Sanofi ADR LLY Eli Lilly and Company

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 16-Oct-2020

$33

$5.27 (19.00%)

$32

8 months 22 days ago
(25-Feb-2026)

17/19 (89.47%)

$-1.02 (-3.00%)

59

Hold Since 09-Sep-2024

$40

$24

1 years 26 days ago
(21-Oct-2025)

1/2 (50%)

$8.57 (27.27%)

127

Hold Since 07-Mar-2024

$22

$31

1 years 9 months 2 days ago
(14-Feb-2025)

3/6 (50%)

$-3.44 (-13.52%)

376

Hold Since 19-Jan-2021

$125

1 years 9 months 24 days ago
(23-Jan-2025)

1/2 (50%)

$17.27 (16.03%)

63

Hold Since 14-Oct-2022

1 years 9 months 24 days ago
(23-Jan-2025)

2/6 (33.33%)

$2.78 (6.01%)

28

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Peter Verdult?

On 2016
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?